Zhang YJ et al. (2007) Hepatocellular carcinoma treated with radiofrequency ablation with or without ethanol injection: a prospective randomized trial. Radiology 244: 599–607
Local ablation for hepatocellular carcinoma (HCC) is recommended for patients who cannot undergo lesion resection and as a palliative treatment before liver transplantation. Radiofrequency ablation (RFA) and percutaneous ethanol injection (PEI) are two ablative therapies that have been widely used in patients with HCC; however, the complete tumor necrosis rate achieved with these therapies in tumors larger than 5 cm is unsatisfactory. To test the hypothesis that the combined use of RFA and PEI might result in greater patient survival than the use of RFA alone, Zhang and colleagues conducted a prospective randomized trial.
In this trial, 133 patients were randomized to receive RFA and PEI (n = 66; 86% male), or RFA alone (n = 67; 87% male). Overall survival rates for the RFA + PEI group were significantly higher than those for the RFA-only group at both 3 and 5 years (P = 0.01 and P = 0.03, respectively). Stratification by tumor size revealed that patients with 3.1–5.0 cm tumors had a significantly higher 3-year overall survival rate when treated with RFA and PEI than when treated with RFA alone (P = 0.04); rates of 3-year overall survival did not differ between the two treatment groups in patients with tumors 5.1–7 cm or <3.0 cm in size. Local recurrence was significantly lower in the RFA + PEI group than in the RFA-alone group (P = 0.01).
Taken together, these results indicate that a treatment regimen that combines RFA and PEI produces better local tumor control and long-term survival in HCC than does RFA alone.
Rights and permissions
About this article
Cite this article
Combined RFA and ethanol injection produces better outcomes than RFA alone in HCC. Nat Rev Clin Oncol 4, 676 (2007). https://doi.org/10.1038/ncponc0939
Issue Date:
DOI: https://doi.org/10.1038/ncponc0939